Skip to content

Intraoperative Hyperspectral Imaging for Fluorescence Guided Surgery in Low Grade Gliomas

Intraoperative Hyperspectral Imaging for Real-time Fluorescence-guided Surgery of Low Grade Glioma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05397574
Acronym
Neuro-qFHSI
Enrollment
60
Registered
2022-05-31
Start date
2022-09-01
Completion date
2025-06-30
Last updated
2023-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor, Neuro-Oncology, Neurosurgery

Brief summary

The purpose of this study is to obtain images of brain tumours during surgery using a new type of surgical camera. The study will assess how the information obtained from the images during surgery matches the removed tissue. Data will also be used to develop the system's key computer-processing features. This will enable real-time information to be given to the surgeon whilst they are performing the procedure and has the potential to make neurosurgery safer and more precise.

Detailed description

High grade gliomas (HGG) and low grade gliomas (LGG) are the commonest CNS cancers, with LGGs accounting for 6.4% of all adult cases (Ostrom 2019). Despite LGGs typically being slow-growing, over 70% of them transform into higher-grade tumours or become aggressive within a decade (Jooma 2019). Median survival for LGG patients spans 5.6 to 13.3 years (Brown 2019). Gross total resection (GTR) improves 5-year LGG survival rates from 60% to 90% when compared to subtotal resection. However, GTR (\>96% tumour removal) is frequently not achieved because despite advanced techniques being available, surgeons are unable to clearly visualise the tumour and its boundaries in real-time during surgery. There is an acute need to improve outcomes for affected brain tumour patients. Patients undergoing surgery have significantly improved outcomes and increased life expectancy if complete tumour removal is achieved. However, close to 30% of patients are left with residual tumour tissue after surgery. Successful surgery indeed mandates maximal safe tumour removal: surgeons need to avoid damaging sensitive areas that undertake vital functions and preserve crucial nerves and blood vessels. Even with the most advanced current techniques, it is not possible to always identify tumour and critical structures reliably during surgery. Furthermore, because one cannot objectively measure the blood supply and oxygenation of brain tissue during surgery, it is difficult to judge if injury is being caused during the operation. To address the pressing clinical need of improved surgical precision and patient safety during low grade glioma surgery, we aim to develop an imaging system capable of quantitative wide-field fluorescence imaging for seamless real-time surgical guidance. This project aims to improve patient survival by delivering a precise assistive tool for neurosurgeons performing LGG surgery by evaluating this device in patients undergoing glioma surgery.

Interventions

None listed

Sponsors

King's College London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18 years and over * Patients with a diagnosis of a probable glioma (any grade), who are scheduled for elective surgery * Patients able to provide written informed consent

Exclusion criteria

* Patients under 18 years of age * Patients who have previously had brain surgery * Patients unable to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Correlation of qFHSI data with histological analysis of the corresponding biopsied pathological tissue6-12 monthsTo correlate ex vivo and in vivo qFHSI data with histological analysis of the corresponding biopsied glioma tissue

Secondary

MeasureTime frameDescription
Safety of qFHSI in surgery24-36 monthsTo demonstrate safety of our intraoperative qFHSI device during glioma surgery
Tissue diagnosis24 monthsTo collect ex vivo and in vivo qFHSI data during glioma surgery for tissue analysis, algorithmic development and testing
Accuracy of biophotonics algorithm24-36 monthsTo evaluate accuracy of the computational biophotonics algorithm to determine 5-ALA-PpIX concentration in imaged tissue
Qualitative assessment24-36 monthsA qualitative assessment of the impact that using the device has on surgical workflow

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026